Product information and disease descriptionPlace of product in therapyDisease description
Clinical presentation - signs and symptoms
10 evidence topics · 9 sources
Asymptomatic course: detection by imaging or liver chemistries
“In most patients, NAFLD is asymptomatic or associated with vague symptoms, often leaving patients undiagnosed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NAFLD are most commonly referred with incidentally noted hepatic steatosis on imaging or elevated liver chemistries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Physician-reported signs and symptoms survey: US adults with MASH, 2019 and 2022
“We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fourteen prespecified individual physician-reported features of MASH were evaluated by the survey: fatigue, sleep disturbance, insomnia, general weakness, unexplained weight loss, hair loss, changes to personality, memory loss, jaundice, aching/discomfort in upper right abdomen, itchy skin, swelling in the legs/ankles/feet, tendency to bleed and bruise more easily, and swelling of the abdomen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 14 reported signs and symptoms, 11 were significantly associated with both physician-stated fibrosis stage and/or AASLD-derived risk category.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
|---|---|---|---|---|
| None | “167 (39.4)”View highlighted excerpt for this quote | “58 (41.1)”View highlighted excerpt for this quote | “6 (20.0)”View highlighted excerpt for this quote | “9 (11.0)”View highlighted excerpt for this quote |
Constitutional symptoms: fatigue, sleep disturbance, and general weakness
“Non-specific symptoms of fatigue, sleep disturbance, and general weakness associated with MASH and other conditions predicted work impact in low-risk MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In all patients, fatigue was the most reported symptom (48.1%, n = 1,268/2,636) followed by sleep disturbance (25.3%, n = 667/2,636), and general weakness (23.7%, n = 625/2,636; Table S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fatigue and pruritus: adults with bridging fibrosis or compensated cirrhosis due to NASH, STELLAR 3 and 4 baseline
“Specifically, PROs (Short Form–36, Chronic Liver Disease Questionnaire–NASH, Euro‐Qol 5 Dimension, and Work Productivity and Activity Impairment instruments) were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conclusion: Clinically significant fatigue and pruritus are common in patients with advanced NASH, and these symptoms negatively affect PROs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fatigue, pruritus, and sleep disorders: adults with MASLD in the Global NAFLD/MASLD Registry
“Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 1-year follow-up, over half of the patients with baseline symptoms continued to experience them, and 14% to 18% developed de novo symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Abdominal and skin symptoms: right upper quadrant discomfort, pruritus, and jaundice
“MASH has been associated with symptoms such as fatigue, abdominal pain, and poor sleep quality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
|---|---|---|---|---|
| Aching/discomfort in upper right abdomen | “43 (10.1)”View highlighted excerpt for this quote | “15 (10.6)”View highlighted excerpt for this quote | “2 (6.7)”View highlighted excerpt for this quote | “23 (28.0)”View highlighted excerpt for this quote |
| Itchy skin | “35 (8.3)”View highlighted excerpt for this quote | “13 (9.2)”View highlighted excerpt for this quote | “5 (16.7)”View highlighted excerpt for this quote | “10 (12.2)”View highlighted excerpt for this quote |
| Jaundice | “14 (3.3)”View highlighted excerpt for this quote | “3 (2.1)”View highlighted excerpt for this quote | “1 (3.3)”View highlighted excerpt for this quote | “8 (9.8)”View highlighted excerpt for this quote |
Cognitive symptoms: memory loss and changes to personality
“Obesity and cognitive impairment are also common in individuals with MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
|---|---|---|---|---|
| Memory loss | “11 (2.6)”View highlighted excerpt for this quote | “3 (2.1)”View highlighted excerpt for this quote | “0 (0.0)”View highlighted excerpt for this quote | “7 (8.5)”View highlighted excerpt for this quote |
| Changes to personality | “9 (2.1)”View highlighted excerpt for this quote | “4 (2.8)”View highlighted excerpt for this quote | “0 (0.0)”View highlighted excerpt for this quote | “4 (4.9)”View highlighted excerpt for this quote |
“Patients were grouped as: early fibrosis (stage 0–2) without additional CVRM comorbidities (EFnoC); early fibrosis with additional CVRM comorbidities (EFwC); or advanced fibrosis (stage 3–4) with additional CVRM comorbidities (AFwC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with AFwC had significantly higher symptom burden compared with those with EFnoC across multiple symptoms (fatigue, p = 0.0006; itchy skin, p = 0.0191; emotional impact, p = 0.0073; activity limitations, p <0.0001; cognitive symptoms, p = 0.0012; and social impact, p = 0.0007; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric symptoms: anxiety and depression in adults with diagnosed NASH
“After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544), reported significantly lower (worse) mental (MCS 43.19 vs. 46.22, p = 0.010) and physical (PCS 42.04 vs. 47.10, p < 0.001) status, higher % with anxiety (37.5% vs 25.5%, p = 0.006) and depression (43.4% vs 30.1%, p = 0.004),” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More NASH patients reported anxiety (37.5% vs. 25.5%, p = 0.006) and depression (43.4% vs. 30.1%, p = 0.004), but sleep difficulties did not differ between cohorts (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical examination: features of insulin resistance and of advanced liver disease
“Body fat distribution (eg, android vs. gynoid, lipodystrophic), features of insulin resistance (eg, dorsal-cervical fat pad, acanthosis nigricans), features of advanced liver disease (eg, firm liver, splenomegaly, prominent abdominal veins, ascites, gynecomastia, spider angiomata, palmar erythema)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Initial evaluation of such patients should include screening for metabolic comorbidities, assessment of alcohol intake, and exclusion of other causes of liver disease as well as physical examination to identify signs of insulin resistance and advanced liver disease (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Signs of fluid retention, bleeding, and hepatic decompensation
| Physician-reported sign or symptom, n (%) | Overall (n = 424) | AASLD-derived low risk (n = 141) | AASLD-derived indeterminate risk (n = 30) | AASLD-derived high risk (n = 82) |
|---|---|---|---|---|
| Swelling in legs, ankles, feet | “42 (9.9)”View highlighted excerpt for this quote | “11 (7.8)”View highlighted excerpt for this quote | “1 (3.3)”View highlighted excerpt for this quote | “20 (24.4)”View highlighted excerpt for this quote |
| Swelling of abdomen | “26 (6.1)”View highlighted excerpt for this quote | “1 (0.7)”View highlighted excerpt for this quote | “0 (0.0)”View highlighted excerpt for this quote | “16 (19.5)”View highlighted excerpt for this quote |
| Tendency to bleed and bruise more easily | “9 (2.1)”View highlighted excerpt for this quote | “1 (0.7)”View highlighted excerpt for this quote | “0 (0.0)”View highlighted excerpt for this quote | “6 (7.3)”View highlighted excerpt for this quote |
“The principal outcomes included death from any cause, hepatic decompensation (clinically apparent ascites, overt encephalopathy, or variceal hemorrhage),” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Encephalopathy (in 30 patients) and ascites (in 19) were the most common new decompensation events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote